Nonprofit advancing cardiovascular research, education, and care in the U.S.
The Saudi Ministry of Health has warned that popular diet trends encouraging stopping prescribed diabetes medications pose serious health risks. Officials urge consulting doctors and nutritionists, and emphasize balanced diets with medical supervision. Experts warn the trend can lead to emergency care and nutrient deficiencies.
Danone has filed a lawsuit in Manhattan federal court alleging Chobani inflates protein claims on multiple-serving tubs of Chobani 20G Protein, a rival to Danone’s Oikos Pro. The case underscores how protein claims are shaping competition in the US amid rising GLP-1 weight-loss drug use. Danone says Chobani’s labeling misleads consumers and undercuts its pricing. Chobani rejects the allegations; analysts note concerns over capacity and competitive dynamics.
Heat waves have intensified health risks, worsening heart and kidney conditions, triggering heat exhaustion, and contributing to inflammatory issues. Experts urge hydration, shade, and cooling measures as high temperatures persist and climate change drives higher heat.
A wave of hot weather has triggered new warnings about how heat changes physiology and mood. Experts say heat triggers vascular changes, dehydration risk, and cognitive and mood shifts, with women facing particular risks. Readers are advised to stay hydrated, avoid peak heat, and monitor vulnerable groups.
Preliminary medical examiner findings indicate an aortic dissection linked to artery hardening has caused the death of a sitting senator. Reports describe sudden chest or back pain and rapid onset of life-threatening symptoms; speedy treatment is critical.
Graham has died at 71 after a suspected brief illness. Medical examiner findings indicate an aortic dissection linked to arteriosclerosis as the likely cause; official cause will follow toxicology and microscopic tests. Social media claims of foul play are unfounded according to preliminary reports. Authorities have noted FBI assistance at Graham’s home.
The FDA has approved Lipfendra, Merck’s oral PCSK9 inhibitor, to lower LDL cholesterol in patients on statins. Trials show ~55-60% LDL reductions; the pill will be sold at about $315/month and must be taken on an empty stomach. Analysts see potential peak sales in the billions as injectable rivals face competition and access barriers.